ADC Therapeutics SA
Commercial-stage biotech developing antibody-drug conjugates for cancer therapy.
ADCT | US
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- BIOPOLE, 1066 EPALINGES
- Website:
- https://adctherapeutics.com/
- Sector:
- Manufacturing
Description
ADC Therapeutics SA is a commercial-stage biotechnology company pioneering the development of antibody-drug conjugates (ADCs) for cancer therapy. The company focuses on creating highly potent and targeted ADCs to treat hematologic malignancies and solid tumors, addressing significant unmet medical needs. Its primary product, ZYNLONTA® (loncastuximab tesirine-lpyl), is an FDA-approved anti-CD19 ADC for adults with relapsed or refractory large B-cell lymphoma. The company's research and development pipeline includes a next-generation PSMA-targeting ADC that utilizes a differentiated exatecan-based payload with a novel hydrophilic linker, aimed at treating solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all ADC Therapeutics SA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ADC Therapeutics SA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ADC Therapeutics SA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
